Apraxia for differentiating Alzheimer’s disease from subcortical vascular dementia and mild cognitive impairment

This article was published in the following Dove Press journal:
Neuropsychiatric Disease and Treatment
8 July 2013
Number of times this article has been viewed

Abstract: Although ideomotor limb apraxia is considered to be a typical sign of cortical pathologies such as Alzheimer’s disease (AD), it has been also reported in subcortical neurodegenerative diseases and vascular lesions. We aimed to investigate the difference between AD, subcortical vascular dementia (SVaD) and mild cognitive impairment (MCI) patients by means of ideomotor limb apraxia frequency and severity. Ninety-six AD, 72 SVaD, and 84 MCI patients were assessed with the mini-mental status examination (MMSE), clinical dementia rating (CDR) and the apraxia screening test of TULIA (AST). Apraxia was significantly more frequent in the AD patients (32.3%) than in both of the SVaD (16.7%) and MCI (4.8%) patients. The frequency of apraxia was also significantly higher in SVaD patients than in MCI patients. AD patients had significantly lower apraxia scores than both SVaD and MCI patients. In addition, a significant difference was found between SVaD and MCI patients in terms of apraxia scores. These results suggest that the widespread belief of the association between apraxia and cortical dementias is not exactly correct. The significant difference between both of the dementia groups and the MCI patients suggests that the absence of apraxia can be an indicator for MCI diagnosis.

Keywords: apraxia, Alzheimer’s disease, subcortical vascular dementia, mild cognitive impairment

Introduction

The two most common forms of senile dementia, Alzheimer’s disease (AD) and vascular dementia (VaD), share many of the same clinical signs and symptoms. Both diseases are characterized by cognitive decline, functional deterioration and neuropsychiatric symptoms that may present as behavioral alterations.1 Vascular disease risk factors such as hypertension, diabetes mellitus, obesity, hypercholesterolemia and vascular changes in the white matter of the brain may not only be present in vascular dementia, but also in Alzheimer’s disease.2,3 These shared features always cause difficulties for the differential diagnosis of these two diseases, especially for the insidious onset of subcortical vascular dementia (SVaD) due to small-vessel disease, which leads to lacunar infarcts and the demyelination of white matter and deep subcortical gray and white matter. Although it is generally accepted that episodic memory impairment, dyscalculia, agnosia, apraxia, and aphasia are more prominent in AD and that executive/attentional processing, semantic memory and visuospatial/perceptual function are more impaired in vascular dementia, especially in patients with SVaD, there is a lack of a uniformly identified cognitive, clinical, imaging and pathological profile typical of SVaD.4,5

Ideomotor limb apraxia, which is the most common subtype of apraxia, is the disturbance of planning and the execution of motor activity without any dysfunction...
of the motor or sensory nervous system or the lack of understanding and motivation.\textsuperscript{6} Dysfunction has been conventionally localized on the left fronto-parieto-temporal cortex, which has been implicated in processing movements of relatively high complexity, planning and sequencing movements. Bihemispheric lesions of the deep white matter, the commissural tracts or the basal ganglia have also been reported as a cause of ideomotor apraxia.\textsuperscript{7-10} These reports suggest that an interruption in the association or commissural tracts of relative cortical areas can also cause the symptom of ideomotor apraxia. It is still accepted as a diagnostically indicative sign for Alzheimer’s disease.\textsuperscript{11}

A small study reported that the frequency of apraxia in mild cognitive impairment patients was not different from that of the age-matched healthy population. Retrospective analyses have shown that only MCI patients who subsequently proceeded to a clinical diagnosis of AD were significantly slower than controls in completing sequential movement tasks despite unimpaired performance.\textsuperscript{12} These results suggested that the absence of apraxia can be one of the clinical indicators for differentiating MCI from the other types of dementia.

In this study, we hypothesized that presence of apraxia may be an indicator to differentiate SVaD and MCI patients from mild to moderate AD patients and we investigated the difference in ideomotor apraxia frequency amongst AD, SVaD and MCI patients and the relationship between the dementia severity and the presence of ideomotor apraxia in each group of cognitive disease patients.

Materials and methods

The patients’ data were retrospectively gathered from two neurodegenerative diseases units (Eskisehir Osmangazi University Medical Faculty and Marmara University Medical Faculty Neurology Clinics), which were participating in the Turkua Alzheimer Working (TAC) Group. This Turkish web-based dementia registry includes neuropsychiatric and cognitive scales that are commonly used for dementia assessment and is currently being used in 18 dementia referral centers across Turkey.\textsuperscript{13} In this registry, patients are recorded with their detailed neuropsychiatric assessments including the Neuropsychiatric Inventory (NPI). Ninety-six consecutive AD, 72 subcortical SVaD and 84 MCI patients were recruited from the web-based data of the two centers. The study was approved by the local ethics committee. An informed consent had been taken from all patients for this registry.

The AD diagnosis was based on the DSM IV-TR and NINDS-ADRDA criteria.\textsuperscript{11} SVaD patients met the criteria for vascular dementia also proposed by the DSM IV-TR and NINDS-AIREN. All of the patients showed at least two of the following focal neurological symptoms or signs: facial palsy, dysarthria, dysphagia, pathologic laughing or crying, weakness or sensory loss of limbs, hyperactive deep tendon reflexes, extensor plantar responses, rigidity of limbs, axial rigidity, bradykinesia, hemiplegic gait, stooped posture, short-step gait, festinating gait, shuffling gait, decreased arm swing while walking, and multi-step turning. All of the patients also had “severe” ischemic changes associated with small-vessel disease. These changes were defined by high signal intensity (HSI) on T2-weighted or FLAIR images corresponding to grade 3 of the Fazekas criteria.\textsuperscript{14} Brain MRI scans confirmed the absence of structural lesions such as intracranial hemorrhage, tumor, traumatic brain injury, or hydrocephalus. Patients with any cortical or subcortical territory infarction were also excluded. Both amnestic and non-amnestic MCI patients were included. The diagnosis of MCI was consistent with the criteria proposed by Petersen and colleagues.\textsuperscript{15} All of the AD patients were in the mild to moderate stage of the disease according to the Global Deterioration Scale/ Functional Assessment Staging system.\textsuperscript{16}

Apraxia was examined using the Apraxia Screening Test of TULIA (AST), which has high diagnostic accuracy (95% sensitivity and 100% specificity) in stroke.\textsuperscript{17} The AST requires the performance of 12 gestures in two domains: (1) imitation including one meaningless gesture, one intransitive (communicative) gesture and five transitive (tool-related) gestures and (2) pantomime including two intransitive gestures and three transitive gestures. The AST is a bedside test, and its administration requires approximately 3 minutes. Both arms were tested separately. The performance was dichotomously (fail: 0, pass: 1) scored by the investigators immediately after the patient’s performance. The scoring method is described in detail elsewhere.\textsuperscript{17} A validated Turkish version of the mini-mental status examination (MMSE) was used to evaluate the cognitive status.\textsuperscript{18} The clinical dementia rating scale was applied to all of the patients for staging the severity of the dementia.\textsuperscript{19}

SPSS 15 (SPSS Inc, Chicago, IL, USA) was used for statistical analyses. Continuous variables were expressed as mean ± SD and were compared between the patients with and without prior stress tests using the one-way ANOVA test with the post-hoc Tukey test. Categorical variables were expressed as frequency percentages and were compared between the groups using the chi-square test or the Fisher exact test as appropriate.\textsuperscript{20} Statistically significant α level was accepted as 0.05 and it was two-sided.
Results
No significant differences were found between the AD and SVaD groups for each demographic group. There were no significant differences amongst the three groups in terms of sex ratio and age. Compared to the AD and SVaD groups, the MCI group had significantly higher MMSE scores and lower disease duration and CDR ($P < 0.001$, for each variable) (Table 1). Although MMSE and CDR scores were better in the SVaD group than in the AD group, the difference was found to be insignificant ($P > 0.05$, for each variable).

Apraxia was significantly more frequent in AD disease patients (32.3%, $n = 31$) than both SVaD (16.7%, $n = 12$) ($X^2 = 4.787$ at $df = 1$, $P = 0.0287$) and MCI (4.8%, $n = 4$) ($X^2 = 18.778$ at $df = 1$, $P < 0.005$) patients. The frequency of apraxia was also significantly higher in SVaD patients than the MCI patients ($X^2 = 6.545$ at $df = 1$, $P = 0.0105$). When we compared the groups according to the apraxia scores, we observed that AD patients had significantly lower apraxia scores than both of the SVaD and MCI patients (odds ratio: $5.04$ [95% Confidence interval (CI): $1.84–11.73$, $P < 0.05$] and odds ratio: $4.17$ [95% CI: $2.67–9.87$, $P < 0.001$, respectively). In addition, a significant difference was found between the SVaD and MCI patients in terms of apraxia scores (odds ratio: $3.12$ [%95 CI: $1.12–5.71$, $P < 0.05$] (Figure 2).

Discussion
Although a large number of studies have revealed many aspects of the pathophysiology of AD, no strongly specific biological or laboratory markers for this disease have been detected. This paucity is a possible reason for low diagnostic accuracy, especially in the early stages of the disease in which the disease is often confused with other forms of dementia, particularly vascular dementia. With the lack of a specific diagnostic marker, the diagnosis is still based primarily on clinical findings. The most common and prominent presentation is the impairment of anterograde episodic memory. The disease progression over time leads to involvement of other cognitive domains in addition to memory, including visuospatial function and praxis, language, and executive skills. In our study with AD and SVaD patients with similar disease duration and dementia severity scores, apraxia seems to be a significant differential marker between these diseases, but it must be noted that SVaD patients can also have significant ideomotor apraxia. Therefore, apraxia, unaccompanied by other signs of dementia, is a weak differential diagnosis parameter for AD and SVaD.

Although apraxia is accepted as one of the diagnostic clinical variables for AD, there are a few studies about its diagnostic value. In one of the early studies, Kramer et al investigated the frequency of apraxia with agnosia and aphasia in groups of cortical (probable AD) dementias and a heterogeneous group of subcortical dementias (Parkinson’s disease and normal pressure hydrocephalus); they reported that only aphasia had been significantly more frequent in cortical dementias and had a very low diagnostic sensitivity, specificity and total predictive value for all three symptoms. These authors concluded that cortical and subcortical dementias cannot be reliably dissociated on the basis of apraxia, aphasia or agnosia. In a similar recent report assessing the occurrence of ideomotor

![Figure 1](https://www.dovepress.com/)

**Figure 1** Apraxia frequency in AD, SVaD and MCI patients.

**Abbreviations:** AD, Alzheimer’s disease; SVaD, subcortical vascular dementia; MCI, mild cognitive impairment.

**Table I** Demographic data of the study population

<table>
<thead>
<tr>
<th></th>
<th>AD patients</th>
<th>SVaD</th>
<th>MCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>96</td>
<td>72</td>
<td>84</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>41/55</td>
<td>32/40</td>
<td>43/41</td>
</tr>
<tr>
<td>Age (years ± SD)</td>
<td>73.32 ± 11.43</td>
<td>74.43 ± 11.84</td>
<td>68.66 ± 9.97</td>
</tr>
<tr>
<td>Disease duration (years ± SD)</td>
<td>6.1 ± 3.2</td>
<td>5.4 ± 4.1</td>
<td>2.1 ± 1.9*</td>
</tr>
<tr>
<td>CDR</td>
<td>1.19 ± 0.84</td>
<td>0.99 ± 0.71</td>
<td>0.44 ± 0.19*</td>
</tr>
<tr>
<td>MMSE</td>
<td>17.16 ± 8.45</td>
<td>19.4 ± 7.72</td>
<td>25.42 ± 4.11*</td>
</tr>
</tbody>
</table>

*Notes: $\alpha < 0.05$; $\beta < 0.001$.

**Abbreviations:** AD, Alzheimer’s disease; SVaD, subcortical vascular dementia; MCI, mild cognitive impairment; SD, standard deviation; CDR, clinical dementia rating; MMSE, mini-mental status examination.

![Figure 2](https://www.dovepress.com/)

**Figure 2** Mean apraxia scores of AD, SVaD and MCI patients.

**Abbreviations:** AD, Alzheimer’s disease; SVaD, subcortical vascular dementia; MCI, mild cognitive impairment.
apraxia in AD and Huntington disease patients, the authors concluded that ideomotor apraxia was a common sign in both groups of patients. Furthermore, they reported that significantly more Huntington disease patients had been classified as apraxic -- according to the hands' and finger imitation and pantomimic subtypes -- than AD patients. However, our study found that apraxia was more frequent in AD than the SVaD patients. This inconsistency between our results and those of the other subcortical dementia studies could be the result of the difference in the pathogenesis and lesion localization of neurogenerative and vascular subcortical dementias. For example, in Huntington disease, prominent heterogeneously cortical dysfunction overlapping with the brain areas of praxis function, even in early stages of the disease, can be a different pathological process from SVaD. As the authors of the Huntington disease study concluded, the cortical degeneration during the disease process may contribute highly to the development of apraxia. Previous studies have reported that thalamic and basal ganglia vascular lesions were more associated with apraxia. However, our SVaD group had heterogeneous subcortical lesion localization, and the basal ganglia lesions were not separately investigated in the present study. This approach could be the reason for the difference between our results and those of previous neurodegenerative dementia studies. Significantly lower apraxia scores in AD patients than in SVaD patients with similar disease duration may suggest that praxis function is affected earlier and more severely in the neurodegenerative process. Without any pathologically proven diagnosis, however, our study is insufficient to make this conclusion.

In our study, the frequency of apraxia in SVaD patients (16.7%) was significantly higher than in MCI (4.8%) patients. Although there is insufficient data in the literature, the frequency of apraxia in subcortical stroke patients was reported to be 33.3% by a previous study. The authors of that study used a different apraxia test, the Movement Imitation Test, to assess the patients, and they included all of the stroke patients regardless of the presence of dementia. This methodological difference could explain the frequency disparity between our results and those of that study. These findings may suggest a methodological problem in the assessment methods for apraxia or the difference between the assessed groups of patients between the studies. For example, apraxia is a well-recognized diagnostic sign in AD, but the exact frequency is still controversial. The frequency has a wide range, from 33% to 77%. The assessment tests used in the studies, the stage of illness, disease severity, and the psychological status of patients can influence the results.

The apraxia assessment method may be the limitation of this study. We used a screening test called the Apraxia Screening of TULIA (AST) that comprises 12 items extracted from the more comprehensive test of upper limb apraxia, TULIA by item reduction analysis. The AST is a simple bedside test that was previously validated for stroke and Parkinson’s disease patients with high clinimetric standards. The validation for both vascular and neurodegenerative disease patients was the reason for selecting this test for our study. Although a high diagnostic sensitivity and specificity for the presence of apraxia in stroke and Parkinson’s disease patients have been reported, the reliability of this test in dementia may be questionable. Reliable results of screening for apraxia in multiple sclerosis have been reported in a recent study. However, it must be kept in mind that this test is only a fast screening test and does not allow for the subclassification of limb apraxia.

This study was designed as a retrospective, recorded data analyzing study. This can also be a limitation for our results, but it should be noted that all the data have been recorded by specialists in cognitive disorders. Besides the study gives data only from the Turkish population and the results may need to be re-evaluated in different cultures. Absence of a control group that could give information about the apraxia in a normal population, may be another limitation for the study. But we believe that the significant difference for MCI patients seems to be an apperant indicator.

Conclusion

In this study, we investigated the frequency and severity of ideomotor apraxia amongst three different cognitive problems (AD, SVaD and MCI) in addition to whether it is a good clinical marker to differentiate these diseases. Although ideomotor apraxia was observed more commonly and was more severe in the AD patients than in the SVaD and MCI patients, this significant difference was also observed between the SVaD and MCI patients. These results suggest that, contrary to widespread belief, it is not completely accurate to state that apraxia and cortical dementias are associated but do not include subcortical dementias. However, the significant difference between both of the dementia groups and MCI patients suggests that the absence of apraxia can only be a predictor for the diagnosis of MCI and that apraxia can be an additional supporting sign for the existing diagnostic criteria.

Disclosure

Authors have no conflicts of interest to report.
References